MX2020013306A - Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos. - Google Patents

Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.

Info

Publication number
MX2020013306A
MX2020013306A MX2020013306A MX2020013306A MX2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A
Authority
MX
Mexico
Prior art keywords
intensive care
post
halogen compounds
prevention
treatment
Prior art date
Application number
MX2020013306A
Other languages
English (en)
Spanish (es)
Inventor
Mark B Roth
Michael L Morrison
Akiko Iwata
Stephen A Hill
John W Langston
Michael Andrew Insko
Original Assignee
Faraday Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faraday Pharmaceuticals Inc filed Critical Faraday Pharmaceuticals Inc
Publication of MX2020013306A publication Critical patent/MX2020013306A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/18Iodine; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020013306A 2018-06-08 2019-06-07 Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos. MX2020013306A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862682574P 2018-06-08 2018-06-08
US201862730927P 2018-09-13 2018-09-13
US201862730945P 2018-09-13 2018-09-13
PCT/US2019/036154 WO2019237065A1 (en) 2018-06-08 2019-06-07 Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome

Publications (1)

Publication Number Publication Date
MX2020013306A true MX2020013306A (es) 2021-05-12

Family

ID=68770655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013306A MX2020013306A (es) 2018-06-08 2019-06-07 Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.

Country Status (10)

Country Link
US (1) US20210252047A1 (https=)
EP (1) EP3801565A4 (https=)
JP (1) JP2021527130A (https=)
KR (1) KR20210018898A (https=)
CN (1) CN112469422A (https=)
AU (1) AU2019282820A1 (https=)
CA (1) CA3102792A1 (https=)
IL (1) IL279221A (https=)
MX (1) MX2020013306A (https=)
WO (1) WO2019237065A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248335B1 (en) * 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
CZ295765B6 (cs) * 1998-07-29 2005-10-12 Apa - Praha, S.R.O. Léčebný přípravek s virucidním účinkem
GB0525504D0 (en) * 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
MX386702B (es) * 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Also Published As

Publication number Publication date
AU2019282820A1 (en) 2021-01-21
CA3102792A1 (en) 2019-12-12
KR20210018898A (ko) 2021-02-18
EP3801565A4 (en) 2022-04-06
JP2021527130A (ja) 2021-10-11
EP3801565A1 (en) 2021-04-14
CN112469422A (zh) 2021-03-09
US20210252047A1 (en) 2021-08-19
WO2019237065A1 (en) 2019-12-12
IL279221A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
IL285782A (en) Compounds, compositions, and methods for treating disease
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
IL276398A (en) Combined treatment for mastocytosis
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX387115B (es) Métodos para tratar la influenza.
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
IL273169A (en) A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2019009753A (es) Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
SG11202107325TA (en) Methods and compositions for the treatment of fabry disease
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
ZA201705874B (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
EP3969009C0 (en) BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF INTESTINAL BARRIER DISORDERS
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EP4055033A4 (en) Combination therapy to treat brain cancer
EP3669880A4 (en) USE OF miR-18b IN THE PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE AND NEUROMUSCULAR DISEASE
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
JOP20210009A1 (ar) طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
MX2020013306A (es) Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.